CatalYm
Phase 2CatalYm has identified GDF-15 as a key cancer therapy resistance mechanism and is developing a safe and efficacious immune therapy for solid tumors.
Founded
2017
Focus
OncologyImmunology
About
CatalYm has identified GDF-15 as a key cancer therapy resistance mechanism and is developing a safe and efficacious immune therapy for solid tumors.
Company Info
TypePrivate
Founded2017
LocationMartinsried, Germany
StagePhase 2
Contact
SIMILAR COMPANIES
300Microns
Pre-clinical · Munich
BetaSense
Pre-clinical · Berlin
AB Diagnostic Systems
Pre-clinical · Jena
bbi-biotech
Pre-clinical · Berlin
Mireca Medicines
Pre-clinical · Munich
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile